News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,181 Results
Type
Article (42314)
Company Profile (294)
Press Release (672573)
Section
Business (210370)
Career Advice (2091)
Deals (36626)
Drug Delivery (106)
Drug Development (83008)
Employer Resources (175)
FDA (16545)
Job Trends (15393)
News (355890)
Policy (33878)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (2)
Adcomms (21)
Allergies (82)
Alliances (51366)
ALS (85)
Alzheimer's disease (1361)
Antibody-drug conjugate (ADC) (113)
Approvals (16538)
Artificial intelligence (240)
Autoimmune disease (15)
Automation (14)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (188)
Bladder cancer (56)
Brain cancer (26)
Breast cancer (247)
Cancer (1975)
Cardiovascular disease (155)
Career advice (1749)
Career pathing (30)
CAR-T (141)
Cell therapy (395)
Cervical cancer (16)
Clinical research (67161)
Collaboration (770)
Compensation (449)
Complete response letters (24)
COVID-19 (2651)
CRISPR (40)
C-suite (206)
Cystic fibrosis (101)
Data (1870)
Decentralized trials (2)
Denatured (25)
Depression (39)
Diabetes (245)
Diagnostics (6406)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (111)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (83)
Earnings (87738)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114401)
Executive appointments (641)
FDA (17636)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (688)
Gene editing (101)
Generative AI (20)
Gene therapy (285)
GLP-1 (714)
Government (4498)
Grass and pollen (4)
Guidances (48)
Healthcare (18986)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (110)
Indications (27)
Infectious disease (2778)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (45)
Intellectual property (84)
Interviews (322)
IPO (16762)
IRA (47)
Job creations (4055)
Job search strategy (1492)
Kidney cancer (9)
Labor market (33)
Layoffs (469)
Leadership (16)
Legal (8367)
Liver cancer (71)
Lung cancer (284)
Lymphoma (130)
Machine learning (2)
Management (59)
Manufacturing (275)
MASH (60)
Medical device (13394)
Medtech (13399)
Mergers & acquisitions (20318)
Metabolic disorders (637)
Multiple sclerosis (67)
NASH (17)
Neurodegenerative disease (79)
Neuropsychiatric disorders (26)
Neuroscience (1838)
NextGen: Class of 2025 (6636)
Non-profit (4524)
Northern California (2369)
Now hiring (36)
Obesity (347)
Opinion (226)
Ovarian cancer (71)
Pain (85)
Pancreatic cancer (76)
Parkinson's disease (130)
Partnered (18)
Patents (202)
Patient recruitment (91)
Peanut (48)
People (59007)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20830)
Phase II (29553)
Phase III (22149)
Pipeline (918)
Podcasts (73)
Policy (119)
Postmarket research (2654)
Preclinical (8824)
Press Release (68)
Prostate cancer (91)
Psychedelics (31)
Radiopharmaceuticals (248)
Rare diseases (366)
Real estate (6251)
Recruiting (67)
Regulatory (22951)
Reports (46)
Research institute (2365)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (122)
Series B (77)
Service/supplier (12)
Sickle cell disease (52)
Southern California (2049)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3721)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (45)
United States (20887)
Vaccines (672)
Venture capitalists (37)
Webinars (12)
Weight loss (239)
Women's health (32)
Worklife (15)
Date
Today (118)
Last 7 days (552)
Last 30 days (2858)
Last 365 days (34169)
2025 (7519)
2024 (35770)
2023 (40630)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (780)
Alabama (49)
Alaska (7)
Arizona (229)
Arkansas (14)
Asia (40544)
Australia (6496)
California (5425)
Canada (1855)
China (467)
Colorado (242)
Connecticut (255)
Delaware (125)
Europe (86442)
Florida (801)
Georgia (188)
Idaho (57)
Illinois (496)
India (23)
Indiana (294)
Iowa (9)
Japan (138)
Kansas (99)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (823)
Massachusetts (4121)
Michigan (210)
Minnesota (367)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1545)
New Mexico (29)
New York (1558)
North Carolina (922)
North Dakota (7)
Northern California (2369)
Ohio (190)
Oklahoma (14)
Oregon (38)
Pennsylvania (1231)
Puerto Rico (9)
Rhode Island (25)
South America (1160)
South Carolina (17)
South Dakota (1)
Southern California (2049)
Tennessee (92)
Texas (807)
Utah (164)
Virginia (135)
Washington D.C. (57)
Washington State (513)
West Virginia (3)
Wisconsin (50)
715,181 Results for "oric pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
·
5 min read
Press Releases
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
January 27, 2025
·
1 min read
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 7, 2025
March 10, 2025
·
4 min read
Press Releases
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
February 18, 2025
·
10 min read
Press Releases
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
January 13, 2025
·
10 min read
Press Releases
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
February 26, 2025
·
7 min read
Press Releases
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
January 14, 2025
·
6 min read
Biotech Bay
ORIC Pharmaceuticals to Participate in Upcoming June 2024 Investor Conferences
ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in June.
May 29, 2024
·
1 min read
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
4 min read
Biotech Bay
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
ORIC Pharmaceuticals, Inc. announced that on June 3, 2024, ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.
June 7, 2024
·
5 min read
1 of 71,519
Next
